{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,10]],"date-time":"2026-10-10T11:45:06Z","timestamp":1791632706761,"version":"4.3.4"},"reference-count":48,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,21]],"date-time":"2023-12-21T00:00:00Z","timestamp":1703116800000},"content-version":"am","delay-in-days":354,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,1,1]],"date-time":"2023-01-01T00:00:00Z","timestamp":1672531200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100019899","name":"Aviesan","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019899","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"published-print":{"date-parts":[[2023,1]]},"DOI":"10.1016\/j.ejpb.2022.12.006","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T02:46:36Z","timestamp":1671072396000},"page":"141-151","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"special_numbering":"C","title":["Refining the delivery and therapeutic efficacy of cetuximab using focused ultrasound in a mouse model of glioblastoma: An 89Zr-cetuximab immunoPET study"],"prefix":"10.1016","volume":"182","author":[{"given":"Estelle","family":"Porret","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dimitri","family":"Kereselidze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ambre","family":"Dauba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Schweitzer-Chaput","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benoit","family":"Jegot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erwan","family":"Selingue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicolas","family":"Tournier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beno\u00eet","family":"Larrat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony","family":"Novell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Truillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejpb.2022.12.006_b0005","doi-asserted-by":"crossref","DOI":"10.7759\/cureus.8195","article-title":"Rising Incidence of Glioblastoma Multiforme in a Well-Defined Population","author":"Grech","year":"2020","journal-title":"Cureus"},{"issue":"21","key":"10.1016\/j.ejpb.2022.12.006_b0010","doi-asserted-by":"crossref","first-page":"5350","DOI":"10.1111\/febs.12393","article-title":"The epidermal growth factor receptor variant III (EGFRvIII): where wild things are altered","volume":"280","author":"Gan","year":"2013","journal-title":"FEBS J."},{"issue":"4","key":"10.1016\/j.ejpb.2022.12.006_b0015","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1677\/erc.1.00600","article-title":"Epidermal growth factor receptor inhibition strategies in oncology","volume":"11","author":"Harari","year":"2004","journal-title":"Endocr. Relat. Cancer"},{"issue":"5A","key":"10.1016\/j.ejpb.2022.12.006_b0025","first-page":"3355","article-title":"Monoclonal antibody cetuximab binds to and down-regulates constitutively activated epidermal growth factor receptor vIII on the cell surface","volume":"27","author":"Patel","year":"2007","journal-title":"Anticancer Res."},{"issue":"17","key":"10.1016\/j.ejpb.2022.12.006_b0030","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.2165\/00003495-200767170-00008","article-title":"Cetuximab: A Review of its Use in Squamous Cell Carcinoma of the Head and Neck and Metastatic Colorectal Cancer","volume":"67","author":"Blick","year":"2007","journal-title":"Drugs"},{"issue":"4","key":"10.1016\/j.ejpb.2022.12.006_b0035","first-page":"134","article-title":"\u00ab A Comprehensive Review of Clinical Trials on EGFR Inhibitors Such as Cetuximab and Panitumumab as Monotherapy and in Combination for Treatment of Metastatic Colorectal Cancer \u00bb","volume":"7","author":"Yazdi","year":"2015","journal-title":"Avicenna J. Med Biotechnol."},{"issue":"20","key":"10.1016\/j.ejpb.2022.12.006_b0040","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa071834","article-title":"Cetuximab for the Treatment of Colorectal Cancer","volume":"357","author":"Jonker","year":"2007","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.ejpb.2022.12.006_b0045","first-page":"1005","article-title":"Activity of Anti-epidermal Growth Factor Receptor Monoclonal Antibody C225 against Glioblastoma Multiforme","volume":"51","author":"Eller","year":"2002","journal-title":"Neurosurgery"},{"issue":"9","key":"10.1016\/j.ejpb.2022.12.006_b0050","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s40263-017-0456-6","article-title":"EGFR as a Target for Glioblastoma Treatment: An Unfulfilled Promise","volume":"31","author":"Westphal","year":"2017","journal-title":"CNS Drugs"},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0055","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41568-019-0205-x","article-title":"John F. Deeken, Clinical Cancer research, 2007","volume":"20","author":"Arvanitis","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"8","key":"10.1016\/j.ejpb.2022.12.006_b0060","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1093\/neuonc\/noz073","article-title":"Most clinical anti-EGFR antibodies do not neutralize both wtEGFR and EGFRvIII activation in glioma","volume":"21","author":"Greenall","year":"2019","journal-title":"Neuro-Oncol."},{"issue":"9","key":"10.1016\/j.ejpb.2022.12.006_b0065","doi-asserted-by":"crossref","first-page":"6645","DOI":"10.1007\/s12035-019-1561-y","article-title":"The Role of Brain Vasculature in Glioblastoma","volume":"56","author":"Kane","year":"2019","journal-title":"Mol. Neurobiol."},{"issue":"2","key":"10.1016\/j.ejpb.2022.12.006_b0070","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1093\/neuonc\/nox175","article-title":"Is the blood\u2013brain barrier really disrupted in all glioblastomas? A critical assessment of existing clinical data","volume":"20","author":"Sarkaria","year":"2018","journal-title":"Neuro-Oncol."},{"key":"10.1016\/j.ejpb.2022.12.006_b0075","doi-asserted-by":"crossref","unstructured":"T. Martens et al., \u00abInhibition of Glioblastoma Growth in a Highly Invasive Nude Mouse Model Can Be Achieved by Targeting Epidermal Growth Factor Receptor but not Vascular Endothelial Growth Factor Receptor-2\u00bb, Clin. Cancer Res., vol. 14, no 17, p. 5447\u20115458, sept. 2008, doi: 10.1158\/1078-0432.CCR-08-0147.","DOI":"10.1158\/1078-0432.CCR-08-0147"},{"issue":"3","key":"10.1016\/j.ejpb.2022.12.006_b0080","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1007\/s11060-016-2099-8","article-title":"Superselective intraarterial cerebral infusion of cetuximab after osmotic blood\/brain barrier disruption for recurrent malignant glioma: phase I study","volume":"128","author":"Chakraborty","year":"2016","journal-title":"J. Neurooncol."},{"key":"10.1016\/j.ejpb.2022.12.006_b0085","unstructured":"\u00abSuper-selective Intra-arterial Repeated Infusion of Cetuximab for the Treatment of Newly Diagnosed Glioblastoma - Full Text View - ClinicalTrials.gov\u00bb."},{"issue":"11","key":"10.1016\/j.ejpb.2022.12.006_b0095","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.3390\/pharmaceutics12111125","article-title":"Recent Advances on Ultrasound Contrast Agents for Blood-Brain Barrier Opening with Focused Ultrasound","volume":"12","author":"Dauba","year":"2020","journal-title":"Pharmaceutics"},{"issue":"31","key":"10.1016\/j.ejpb.2022.12.006_b0100","doi-asserted-by":"crossref","first-page":"11719","DOI":"10.1073\/pnas.0604318103","article-title":"Noninvasive localized delivery of Herceptin to the mouse brain by MRI-guided focused ultrasound-induced blood-brain barrier disruption","volume":"103","author":"Kinoshita","year":"2006","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2022.12.006_b0105","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.jconrel.2020.08.047","article-title":"Impact of blood-brain barrier permeabilization induced by ultrasound associated to microbubbles on the brain delivery and kinetics of cetuximab: An immunoPET study using 89Zr-cetuximab","volume":"328","author":"Tran","year":"2020","journal-title":"J. Controlled Release"},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0110","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1148\/radiol.2016152444","article-title":"Focused Ultrasound Enhances Central Nervous System Delivery of Bevacizumab for Malignant Glioma Treatment","volume":"281","author":"Liu","year":"2016","journal-title":"Radiology"},{"issue":"3","key":"10.1016\/j.ejpb.2022.12.006_b0115","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1016\/j.jconrel.2012.09.007","article-title":"Ultrasound-mediated blood-brain\/blood-tumor barrier disruption improves outcomes with trastuzumab in a breast cancer brain metastasis model","volume":"163","author":"Park","year":"2012","journal-title":"J. Controlled Release"},{"key":"10.1016\/j.ejpb.2022.12.006_b0120","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/j.jconrel.2016.08.001","article-title":"Growth inhibition in a brain metastasis model by antibody delivery using focused ultrasound-mediated blood-brain barrier disruption","volume":"238","author":"Kobus","year":"2016","journal-title":"J. Controlled Release"},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0125","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1614777114","article-title":"Disrupting the blood\u2013brain barrier by focused ultrasound induces sterile inflammation","volume":"114","author":"Kovacs","year":"2017","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ejpb.2022.12.006_b0130","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1016\/j.expneurol.2013.05.008","article-title":"Amyloid-\u03b2 plaque reduction, endogenous antibody delivery and glial activation by brain-targeted, transcranial focused ultrasound","volume":"248","author":"Jord\u00e3o","year":"2013","journal-title":"Exp. Neurol."},{"key":"10.1016\/j.ejpb.2022.12.006_b0135","doi-asserted-by":"crossref","unstructured":"Y. W. S. Jauw et al., \u00abImmuno-Positron Emission Tomography with Zirconium-89-Labeled Monoclonal Antibodies in Oncology: What Can We Learn from Initial Clinical Trials?\u00bb, Front. Pharmacol., vol. 7, mai 2016, doi: 10.3389\/fphar.2016.00131.","DOI":"10.3389\/fphar.2016.00131"},{"issue":"4","key":"10.1016\/j.ejpb.2022.12.006_b0140","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1038\/nprot.2010.13","article-title":"Conjugation and radiolabeling of monoclonal antibodies with zirconium-89 for PET imaging using the bifunctional chelate p-isothiocyanatobenzyl-desferrioxamine","volume":"5","author":"Vosjan","year":"2010","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.ejpb.2022.12.006_b0145","doi-asserted-by":"crossref","DOI":"10.1111\/j.1349-7006.2008.00945.x","article-title":"Antitumor activity of cetuximab against malignant glioma cells overexpressing EGFR deletion mutant variant III","author":"Fukai","year":"2008","journal-title":"Cancer Sci."},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0150","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.acra.2009.07.027","article-title":"Detecting Epidermal Growth Factor Receptor Tumor Activity In Vivo During Cetuximab Therapy of Murine Gliomas","volume":"17","author":"Gibbs-Strauss","year":"2010","journal-title":"Acad. Radiol."},{"key":"10.1016\/j.ejpb.2022.12.006_b0160","doi-asserted-by":"crossref","unstructured":"G. Hugon et al., \u00ab[18F]2-Fluoro-2-deoxy-sorbitol PET Imaging for Quantitative Monitoring of Enhanced Blood-Brain Barrier Permeability Induced by Focused Ultrasound\u00bb, Pharmaceutics, vol. 13, no 11, p. 1752, oct. 2021, doi: 10.3390\/pharmaceutics13111752.","DOI":"10.3390\/pharmaceutics13111752"},{"key":"10.1016\/j.ejpb.2022.12.006_b0165","doi-asserted-by":"crossref","unstructured":"A. Damont et al., \u00abRadiosynthesis of [ 18 F]DPA\u2010714, a selective radioligand for imaging the translocator protein (18 kDa) with PET\u00bb, J. Label. Compd. Radiopharm., vol. 51, no 7, p. 286\u2011292, juin 2008, doi: 10.1002\/jlcr.1523.","DOI":"10.1002\/jlcr.1523"},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0170","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.neuroimage.2008.03.037","article-title":"High resolution three-dimensional brain atlas using an average magnetic resonance image of 40 adult C57Bl\/6J mice","volume":"42","author":"Dorr","year":"2008","journal-title":"Neuroimage"},{"issue":"4","key":"10.1016\/j.ejpb.2022.12.006_b0175","doi-asserted-by":"crossref","first-page":"512","DOI":"10.2967\/jnumed.114.151621","article-title":"The 18-kDa Mitochondrial Translocator Protein in Human Gliomas: An 11 C-(R)PK11195 PET Imaging and Neuropathology Study","volume":"56","author":"Su","year":"2015","journal-title":"J Nucl Med"},{"key":"10.1016\/j.ejpb.2022.12.006_b0180","doi-asserted-by":"crossref","unstructured":"H. Pigeon et al., \u00abTSPO-PET and diffusion-weighted MRI for imaging a mouse model of infiltrative human glioma\u00bb, Neuro-Oncol., vol. 21, no 6, p. 755\u2011764, juin 2019, doi: 10.1093\/neuonc\/noz029.","DOI":"10.1093\/neuonc\/noz029"},{"key":"10.1016\/j.ejpb.2022.12.006_b0185","doi-asserted-by":"crossref","unstructured":"B. Zinnhardt et al., \u00abCombined PET Imaging of the Inflammatory Tumor Microenvironment Identifies Margins of Unique Radiotracer Uptake\u00bb, Cancer Res., vol. 77, no 8, p. 1831\u20111841, avr. 2017, doi: 10.1158\/0008-5472.CAN-16-2628.","DOI":"10.1158\/0008-5472.CAN-16-2628"},{"key":"10.1016\/j.ejpb.2022.12.006_b0190","doi-asserted-by":"crossref","unstructured":"E. L. Werry et al., \u00abRecent Developments in TSPO PET Imaging as A Biomarker of Neuroinflammation in Neurodegenerative Disorders\u00bb, Int. J. Mol. Sci., vol. 20, no 13, p. 3161, juin 2019, doi: 10.3390\/ijms20133161.","DOI":"10.3390\/ijms20133161"},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0195","doi-asserted-by":"crossref","DOI":"10.1186\/s12974-019-1543-z","article-title":"In vivo imaging of sterile microglial activation in rat brain after disrupting the blood-brain barrier with pulsed focused ultrasound: [18F]DPA-714 PET study","volume":"16","author":"Sinharay","year":"2019","journal-title":"J Neuroinflammation"},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0200","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/glia.440150103","article-title":"A qualitative and quantitative study of the glial cells in normal and athymic mice","volume":"15","author":"Htain","year":"1995","journal-title":"Glia"},{"issue":"3","key":"10.1016\/j.ejpb.2022.12.006_b0205","doi-asserted-by":"crossref","first-page":"3870","DOI":"10.18632\/oncotarget.13910","article-title":"Quantitative assessment of Zirconium-89 labeled cetuximab using PET\/CT imaging in patients with advanced head and neck cancer: a theragnostic approach","volume":"8","author":"Even","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ejpb.2022.12.006_b0210","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1200\/JCO.2000.18.4.904","article-title":"Phase I Studies of Anti\u2013Epidermal Growth Factor Receptor Chimeric Antibody C225 Alone and in Combination With Cisplatin","volume":"18","author":"Baselga","year":"2000","journal-title":"JCO"},{"issue":"9","key":"10.1016\/j.ejpb.2022.12.006_b0215","doi-asserted-by":"crossref","first-page":"1596","DOI":"10.1093\/annonc\/mdp032","article-title":"Stratified phase II trial of cetuximab in patients with recurrent high-grade glioma","volume":"20","author":"Neyns","year":"2009","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0225","doi-asserted-by":"crossref","DOI":"10.1186\/1476-4598-11-47","article-title":"Tumor penetration and epidermal growth factor receptor saturation by panitumumab correlate with antitumor activity in a preclinical model of human cancer","volume":"11","author":"Freeman","year":"2012","journal-title":"Mol Cancer"},{"issue":"37","key":"10.1016\/j.ejpb.2022.12.006_b0230","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.1807105115","article-title":"Mechanisms of enhanced drug delivery in brain metastases with focused ultrasound-induced blood\u2013tumor barrier disruption","volume":"115","author":"Arvanitis","year":"2018","journal-title":"Proc. Natl. Acad. Sci. U.S.A."},{"issue":"7203","key":"10.1016\/j.ejpb.2022.12.006_b0235","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1038\/nature07205","article-title":"Cancer-related inflammation","volume":"454","author":"Mantovani","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.ejpb.2022.12.006_b0240","doi-asserted-by":"crossref","unstructured":"J. Dimitrova-Shumkovska, L. Krstanoski, et L. Veenman, \u00abDiagnostic and Therapeutic Potential of TSPO Studies Regarding Neurodegenerative Diseases, Psychiatric Disorders, Alcohol Use Disorders, Traumatic Brain Injury, and Stroke: An Update\u00bb, Cells, vol. 9, no 4, p. 870, avr. 2020, doi: 10.3390\/cells9040870.","DOI":"10.3390\/cells9040870"},{"issue":"1","key":"10.1016\/j.ejpb.2022.12.006_b0245","doi-asserted-by":"crossref","first-page":"94","DOI":"10.1007\/s11307-017-1099-1","article-title":"Increased Expression of Translocator Protein (TSPO) Marks Pro-inflammatory Microglia but Does Not Predict Neurodegeneration","volume":"20","author":"Beckers","year":"2018","journal-title":"Mol Imaging Biol"},{"issue":"2","key":"10.1016\/j.ejpb.2022.12.006_b0250","doi-asserted-by":"crossref","first-page":"165","DOI":"10.2967\/jnumed.114.141713","article-title":"Imaging Microglial Activation with TSPO PET: Lighting Up Neurologic Diseases?","volume":"57","author":"Vivash","year":"2016","journal-title":"J. Nucl. Med."},{"issue":"2","key":"10.1016\/j.ejpb.2022.12.006_b0255","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1002\/glia.23716","article-title":"Imaging of translocator protein upregulation is selective for pro\u2010inflammatory polarized astrocytes and microglia","volume":"68","author":"Pannell","year":"2020","journal-title":"Glia"},{"issue":"32","key":"10.1016\/j.ejpb.2022.12.006_b0260","doi-asserted-by":"crossref","first-page":"10809","DOI":"10.1523\/JNEUROSCI.1487-12.2012","article-title":"Reactive Astrocytes Overexpress TSPO and Are Detected by TSPO Positron Emission Tomography Imaging","volume":"32","author":"Lavisse","year":"2012","journal-title":"J. Neurosci."}],"container-title":["European Journal of Pharmaceutics and Biopharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122003009?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0939641122003009?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T16:51:08Z","timestamp":1760547068000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0939641122003009"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,1]]},"references-count":48,"alternative-id":["S0939641122003009"],"URL":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.12.006","relation":{},"ISSN":["0939-6411"],"issn-type":[{"value":"0939-6411","type":"print"}],"subject":[],"published":{"date-parts":[[2023,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Refining the delivery and therapeutic efficacy of cetuximab using focused ultrasound in a mouse model of glioblastoma: An 89Zr-cetuximab immunoPET study","name":"articletitle","label":"Article Title"},{"value":"European Journal of Pharmaceutics and Biopharmaceutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejpb.2022.12.006","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier B.V. All rights reserved.","name":"copyright","label":"Copyright"}]}}